BIVI BioVie Inc. - Common stock

NAS · US · Healthcare · Biotechnology · bioviepharma.com

1.460USD-0.68%Mkt Cap: 12.68M $P/E: —3d ago

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap12.68M USD

Enterprise Value2.31M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-22.07M USD

Revenue/Share—

Last Price1.460 USD

Fiscal Year EndJun 2026

MR QuarterJun 2026

Employees13

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-2.56

PEG—

EV/EBITDA-0.10

EV/Revenue—

P/S—

P/B1.07

EPS (TTM)-3.05

EPS (Forward)-0.57

52W Range

0.820022% of range3.790

52W High3.790 USD

52W Low0.8200 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-214.92%

ROA-154.89%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-19.02M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-87.74%

Net Debt-8.70M USD

Net Debt/EBITDA0.39

Balance Sheet

Debt/Equity0.03

Current Ratio3.59

Quick Ratio2.93

Book Value/Sh1.36 USD

Cash/Share1.19 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay DateNov 22, 2019

Splits

Last Split1:10

Split DateJul 7, 2025

Analyst Consensus

Rating—

Target (Mean)5.255 USD

Upside (mean)+259.9%

Target Range5.000 USD – 5.510 USD

5.000+259.9% to mean5.510

# Analysts2

Ownership

Shares Out.8.68M

Float7.48M

Insiders0.49%

Institutions22.13%

Short Interest

Short Ratio0.2d

Short % Float12.32%

Short % Out.12.26%

Shares Short1.05M

Short (prev mo.)1.25M

Technical

SMA 501.680 (-13.1%)

SMA 2001.516 (-3.7%)

Beta0.74

S&P 52W Chg14.58%

Avg Vol (30d)6.61M

Avg Vol (10d)250.71K

Technical Indicators

RSI (14)39.6

MACD-0.0716

MACD Signal-0.0281

MACD Hist.-0.0435

BB Upper2.191 USD

BB Middle1.749 USD

BB Lower1.308 USD

BB Width50.46%

ATR (14)0.1897 USD

Vol Ratio (20d)0.61x